中国生物工程杂志

［1］ Roberts M J,Bentley M D,Harris J M. Chemistry for peptide and protein PEGylation.Adv Drug Deliv Rev,2002,54(4):459476. 
［2］ Wang Y S,Yongster S,Grace M,et al. Structural and biological characterization of pegylated recombinant interferon alpha2b and its therapeutic applications.Adv Drug Deliv Rev, 2002, 54(4):547570. 
［3］ Reddy K R, Modi M W, Pedder S. Use of peginterferon alfa2a (40KD) (Pegasys) for the treatment of hepatitis C. Adv Drug Deliv Rev, 2002,54,571584. 
［4］ Harris J M, Martin N E, Modi M. Pegylationa novel process for modifying pharmacokinetics. Clin Pharmacokinet,2001,40(7):539551. 
［5］ Ramon J, Saez V, Baez R, et al. PEGylated interferonalpha2b: a branched 40K polyethylene glycol derivative. Pharm Res,2005, 22(8):13741386. 
［6］ Jo Y W, Youn Y S, Lee S H, et al. Longacting interferonalpha2a modified with a trimerstructured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics. Int J Pharm, 2006, 309(12):8793. 
［7］ Bell S J, Fam C M, Chlipala E A, et al. Enhance Circulating HalfLife and Antitumor Actiity of a SiteSpecific Pegylated Interferonα Protein Therapeutic. Bioconjugate Chem, 2008,19(1):299305. 
［8］ Balan S, Choi J W, Godwin A, et al. SiteSpecific PEGylation of Protein Disulfide Bonds Using a ThreeCarbon Bridge. Bioconjugate Chem, 2007,18(1):6176. 
［9］ 牛晓霞，刘金毅，杨轶，等. 集成干扰素突变体Ⅱ的分子构建、表达及提纯. 中国生物工程杂志, 2006,26(12):15. Niu X X , Liu J Y , Yang Y . Chin Biotechnol,2006,26(12):15. 
［10］ 牛晓霞，周敏毅，刘金毅，等. 聚乙二醇定点修饰集成干扰素突变体Ⅱ.中国生物工程杂志,2008,28(4):1720. Niu X X , Zhou M Y, Liu J Y,et al . Chin Biotechnol, 2008,28(4):1720. 
［11］ Bain V G,Kaita K D,Yoshida E M. A phase 2 study to evaluate the antiviral activity, safety,and pharmacokinetics of recombinant human albumininterferon alfa fusion protein in genotype 1 chronic hepatitis C. patients. J Hepatol,2006, 44(4):671678. 
［12］ Zhao H L, Xue C, Wang Y, et al. Circumventing the heterogeneity and instability of human serum albumininterferonalpha2b fusion protein by altering its orientation. J Biotechnol. 2007,131(3):245252. 
［13］ Zhao H L, Xue Q Y, Xue C, et al. Increasing the homogeneity, stability and activity of human serum albumin and interferonα2b fusion protein by linker engineering. Protein Express Purif ,2008, 61(1):7377. 
［14］ 王磊，何剑，肖卫华. 毕赤酵母表达人干扰素α 2b和人IgG免疫球蛋白Fc片段融合蛋白显著延长体内半衰期. 生物工程学报, 2008, 24(1):5362. Wang L, He J, Xiao W H. Chin J Biotechnol, 2008, 24(1):5362. 
［15］ Jones T D, Hanlon M, Smith B J, et al. The development of a modified human IFNalpha2b linked to the Fc portion of human IgG 1 as a novel potential therapeutic for the treatment of hepatitis C virus infection. J. Interferon Cytokine Res, 2004, 24(9): 560572. 
［16］ Ceaglio N, Etcheverrigaray M, Kratje R, et al. Novel longlasting interferon alpha derivatives designed by glycoengineering. Biochimie,2008,90 (3):437449. 
［17］ Drittanti L, Borrelly G, Guyon T, et al. Belerofon:a longlasting and orally available singleamino acid mutant of interferon alpha. J Interferon Cytokine Res , 2007,27:7091709. 
［18］ De Leede L G, Humphries J E, Bechet A C, et al.Novel ControlledRelease LemnaDerived IFNalpha2b (Locteron):Pharmacokinetics, Pharmacodynamics, and Tolerability in a Phase I Clinical Trial. J Interferon Cytokine Res , 2008,28(2):113122. 
［19］ Chan Y P, Meyrueix R, Kravtzoff R et al. Review on Medusa:a polymerbased sustained release technology for protein and peptide drugs. Expert Opin Drug Deliv , 2007, 4(4):441451. 
［20］ Zhang Y M, Yang F, Yang Y Q, et al. Recombinant interferonalpha2b poly(lacticcoglycolic acid) microspheres: pharmacokineticspharmacodynamics study in rhesus monkeys following intramuscular administration. Acta Pharmacol Sin,2008,29(11):13701375. 
［21］ Vyas S P, Rawat M, Rawat A, et al. Pegylated protein encapsulated multivesicular liposomes: a novel approach for sustained release of interferon alpha. Drug Dev Ind Pharm, 2006, 32(6):699707. 
［22］ Ito Y, Saeki A, Shiroyama K, et al. Percutaneous absorption of interferonα by selfdissolving micropiles. J Drug Target, 2008,16(3):243249.